Cineverse Corp. (CNVS) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several challenges: a 3% revenue decline, increased SG&A expenses leading to a net loss, and liquidity concerns with only $2.3 million in cash. The box office underperformance and competitive pressures in technology and micro drama ventures add to the negative sentiment. Despite some positives like streaming growth and improved margins, the overall outlook is clouded by financial and strategic uncertainties, leading to a likely negative stock price reaction.
Key Financial Performance
Total Revenue $12.7 million, down 3% year-over-year. The decline was attributed to timing effects of licensing deals, such as a $1.1 million licensing deal for The Toxic Avenger that will be recognized in future periods.
Operating Margins Grew by 7% year-over-year to 58%. This improvement was due to cost control measures and leveraging efficiencies from Cineverse Services India to manage SG&A spending.
Net Loss $5.5 million compared to $1.2 million in the prior year quarter. The increase in net loss was primarily due to higher SG&A expenses driven by investments in sales, marketing, and technology, as well as start-up costs for the MicroCo venture.
Adjusted EBITDA Negative $3.7 million compared to $0.5 million in the prior year quarter. The decline was attributed to the same factors affecting net loss, including increased SG&A expenses and investments in new initiatives.
Cash and Cash Equivalents $2.3 million as of September 30, 2025, with $5.9 million available on a $12.5 million working capital facility. The decline in cash was due to royalty payments and advance payments for the theatrical slate.
Content Library Valuation Valued at $45 million, significantly higher than the $3.2 million book value. This increase reflects the material asset value not included on the balance sheet.
Streaming Viewers 143.8 million, up 47% year-over-year. This growth was driven by the success of key channels like Barney, Dog Whisperer, and Screambox TV.
Total Minutes Streamed 3.4 billion, up 45% year-over-year. FAST minutes streamed accounted for 3.2 billion of this total, up 47%.
SVOD Subscribers 1.39 million, a 6% increase year-over-year. Growth was supported by the launch of Terrifier 3 and other content initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The Toxic Avenger Unrated: Released on August 29, did not perform well at the box office but is performing well in ancillary distribution markets like VOD, physical, and licensing with Amazon and Hulu. Expected IRR of 40%.
Terrifier 3: Opened at #1 at the box office with $54 million in ticket sales on a $500,000 marketing spend. Demonstrates the success of Cineverse's low-cost, fan-centric film strategy.
Silent Night, Deadly Night and Return to Silent Hill: Upcoming releases with all-in investments projected to be below $5 million each, following the same low-cost, fan-centric strategy.
Air Bud Returns: Nearing completion of principal photography, generating buzz on social media and expected to release in late 2026.
Pan's Labyrinth 20th Anniversary Edition: Cineverse secured a multiyear domestic distribution deal for this classic film, with a marketing campaign starting in May 2026 for a late 2026 release.
Streaming Viewership: Total streaming viewers reached 143.8 million, up 47% year-over-year. Total minutes streamed were 3.4 billion, up 45%.
SVOD Subscribers: Grew to 1.39 million, a 6% increase year-over-year.
Matchpoint Technology: Added more than 20 new customers in the last 100 days, launched Matchpoint 3.0, and expanded internationally. Secured new partners and is under evaluation by major Hollywood studios.
MicroCo Venture: Aimed at becoming a leader in the $8 billion micro drama market. Received funding commitment from a leading venture capital firm and is actively engaging with additional partners.
Cost Management: Focused on controlling costs and leveraging Cineverse Services India to manage SG&A spending.
Content Library Valuation: Updated valuation of $45 million, significantly above the $3.2 million book value.
Advertising Strategy: Preparing for political spending and easing interest rates to boost ad business. Integrating AI-driven metadata repository into ad stack for better audience targeting.
Film Releasing Strategy: Low-cost, fan-centric approach to film releasing, attracting quality directors and producers.
Matchpoint Expansion: Positioning Matchpoint as the operating system for content libraries worldwide through strategic partnerships and acquisitions.
MicroCo Development: Building a platform for micro dramas with a leadership team of industry veterans and AI-native workflows.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenues for the quarter were $12.7 million, down 3% from the prior year quarter. This decline, despite some licensing deals, indicates potential challenges in maintaining consistent revenue growth.
Box Office Performance: The Toxic Avenger Unrated did not perform as well as expected at the box office, which could indicate risks in the company's film portfolio strategy and reliance on theatrical releases.
SG&A Expenses: Increased SG&A expenses due to investments in sales, marketing, and technology have led to a net loss of $5.5 million and negative adjusted EBITDA of $3.7 million for the quarter. This raises concerns about the financial impact of these upfront investments.
Advertising Market Conditions: The advertising environment faced pressure due to macroeconomic concerns, tariff uncertainty, and increased inventory from competitors like Amazon and Netflix. This created choppiness in the category, impacting revenue.
Cash Flow and Liquidity: The company had $2.3 million in cash and cash equivalents as of September 30, with a decline in cash attributed to royalty payments and advance payments for theatrical releases. This could pose liquidity challenges if cash flow does not improve.
Dependence on Licensing Deals: Revenue recognition is heavily influenced by licensing deals, such as the $1.1 million deal for The Toxic Avenger Unrated. This dependency could lead to revenue volatility.
Competitive Pressures in Technology: Matchpoint technology faces a long and complex deal cycle, and while it has potential, the competitive landscape and reliance on large deals could pose risks to its growth trajectory.
Micro Drama Venture Risks: The newly formed MicroCo venture involves significant start-up costs and is entering a fragmented and competitive market. Success is uncertain, and the venture could strain resources if it does not perform as expected.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects strong top and bottom-line results for the remainder of fiscal year 2026 and fiscal year 2027, driven by upfront investments in sales, marketing, and technology.
Film Releases: Upcoming releases include 'Silent Night, Deadly Night' on December 12, 2025, and 'Return to Silent Hill' on January 23, 2026. Both films are expected to follow a low-cost, high-return model with investments below $5 million each.
Future Film Projects: The family film 'Air Bud Returns' is expected to release in late calendar 2026. Additionally, the 20th anniversary edition of 'Pan's Labyrinth' is planned for a late 2026 theatrical release.
Content Library Valuation: The company's content library is valued at $45 million, significantly higher than its book value of $3.2 million, indicating potential for future monetization.
Streaming Growth: Streaming viewers increased by 47% year-over-year, with SVOD subscribers growing by 6%. The company anticipates continued growth in streaming metrics.
Advertising Revenue: Political spending and easing interest rates are expected to lift advertising revenue in fiscal Q4 and early fiscal Q1.
Matchpoint Technology: The Matchpoint platform added over 20 new customers in the last 100 days and is under evaluation by major Hollywood studios, indicating potential for significant recurring revenue.
MicroCo Venture: The MicroCo joint venture aims to become a leader in the $8 billion micro drama market, with significant commitments from venture firms and plans for AI-native platform development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the licensing deal influence expectations for the upcoming slate and change the approach to selecting films?
A:Chris McGurk stated that the licensing deal validated their theatrical releasing strategy, particularly with the success of "Toxic Avenger" in ancillary markets. He emphasized avoiding mixed-genre movies in the future as they are harder to market theatrically.
Q:What is the timing of monetization and expected contribution of Matchpoint over the next 12 to 24 months?
A:Erick Opeka explained that Matchpoint has received positive responses from studios and broadcasters, but the sales cycle can range from 6 to 9 months due to bureaucratic processes. He highlighted Matchpoint's potential to achieve 80%-90% software gross margins and mentioned ongoing pilots with major studios, which could lead to mid-7 to low-8 figure annual revenues per studio.
Q:Review of Unclear Management Responses
A:Management did not avoid any questions directly, but some responses, particularly regarding Matchpoint's timeline and adoption by studios, included generalities and lacked specific numerical details or concrete timelines.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Academy award
Adviser information
Amazon Hulu
Avenger fact
Avenger period
Cannes anniversary
Chief President
Director del
Festival minute
Loffredo Chief
Pan Labyrinth
SGA investment
Senior Adviser
Terrifier
Toxic Avenger
artist
book value
deal Toxic
decline
film distribution
film library
library book
license
licensing deal
line result
loss
marketing campaign
payment
progress
releasing
result remainder
technology sale
top line
valuation
venture
CNVS Transcript
Cineverse Corp. (CNVS) Q4 2026 Earnings Call Transcript
Neutral6-26
Cineverse Corp. (CNVS) Q3 2026 Earnings Call Transcript
Positive2-17
The earnings call highlights strong financial performance, with improved margins and EBITDA, despite a year-over-year revenue decline. Growth in streaming metrics and strategic acquisitions, particularly in Matchpoint, indicate future revenue synergies. The Q&A section reveals positive analyst sentiment towards the company's strategic direction and potential for growth, though some caution is noted due to conservative guidance. Overall, the positive aspects outweigh the negatives, suggesting a stock price increase of 2% to 8%.
Cineverse Corp. (CNVS) Q2 2026 Earnings Call Transcript
Unknown11-14
The earnings call highlights several challenges: a 3% revenue decline, increased SG&A expenses leading to a net loss, and liquidity concerns with only $2.3 million in cash. The box office underperformance and competitive pressures in technology and micro drama ventures add to the negative sentiment. Despite some positives like streaming growth and improved margins, the overall outlook is clouded by financial and strategic uncertainties, leading to a likely negative stock price reaction.
Cineverse Corp. (CNVS) Q1 2026 Earnings Call Transcript
Unknown8-14
The earnings call reveals financial challenges, including a net loss and cash flow concerns, despite revenue growth. The company's investments in new ventures and initiatives like MicroCo carry significant uncertainty and risk. The Q&A highlighted management's lack of clarity on key strategic initiatives, which may raise investor concerns. While there are positive aspects, such as streaming growth and direct advertising success, the overall sentiment leans negative due to financial strain and uncertainty around new ventures.
CNVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
